Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2024 Sep;26(9):3673-3683.
doi: 10.1111/dom.15708. Epub 2024 Jun 20.

Denosumab, for osteoporosis, reduces the incidence of type 2 diabetes, risk of foot ulceration and all-cause mortality in adults, compared with bisphosphonates: An analysis of real-world, cohort data, with a systematic review and meta-analysis

Alex E Henney  1   2   3 , David R Riley  1   2 , Ben O'Connor  4 , Theresa J Hydes  1   2   3 , Matthew Anson  1   2 , Sizheng Steven Zhao  5 , Uazman Alam  1   2   3   6 , Daniel J Cuthbertson  1   2   3
Affiliations
Meta-Analysis

Denosumab, for osteoporosis, reduces the incidence of type 2 diabetes, risk of foot ulceration and all-cause mortality in adults, compared with bisphosphonates: An analysis of real-world, cohort data, with a systematic review and meta-analysis

Alex E Henney et al. Diabetes Obes Metab. 2024 Sep.

Abstract

Aim: To evaluate the impact of denosumab on (i) the incidence of type 2 diabetes (T2D), and (ii) long-term health outcomes (microvascular [neuropathy, retinopathy, nephropathy] and macrovascular [cardiovascular disease, cerebrovascular accident] complications, and all-cause mortality) in patients with T2D, before (iii) combining results with prior studies using meta-analysis.

Methods: A retrospective analysis of data in a large global federated database (TriNetX; Cambridge, MA) was conducted from 331 375 patients, without baseline T2D or cancer, prescribed either denosumab (treatment, n = 45 854) or bisphosphonates (control, n = 285 521), across 83 healthcare organizations. Propensity score matching (1:1) of confounders was undertaken that resulted in 45 851 in each cohort. Secondary analysis further evaluated the impact of denosumab on long-term health outcomes in patients with T2D. Additionally, we systematically searched prior literature that assessed the association between denosumab and T2D. Estimates were pooled using random-effects meta-analysis. Risk of bias and evidence quality were assessed using Cochrane-endorsed tools.

Results: Denosumab (vs. bisphosphonates) was associated with a lower risk of incident T2D over 5 years (hazard ratio 0.83 [95% confidence interval {CI} 0.78-0.88]). Secondary analysis showed significant risk reduction in all-cause mortality (0.79 [0.72-0.87]) and foot ulceration (0.67 [0.53-0.86]). Also, pooled results from four studies (three observational, one randomized controlled trial) following meta-analysis showed a reduced relative risk (RR [95% CI]) for incident T2D in patients prescribed denosumab (0.83 [0.79-0.87]) (I2 = 10.76%).

Conclusions: This is the largest cohort study to show that denosumab treatment is associated with a reduced RR of incident T2D, as well as an associated reduced RR of all-cause mortality and microvascular complications, findings that may influence guideline development in the treatment of osteoporosis, particularly in patients who are at a high risk of T2D.

Keywords: antidiabetic drug; cohort study; database research; diabetes complications; diabetic nephropathy; diabetic neuropathy.

PubMed Disclaimer

Similar articles

See all similar articles

References

REFERENCES

    1. Cho NH, Shaw JE, Karuranga S, et al. IDF diabetes atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018;138:271‐281.
    1. Lin HH, Hsu HY, Tsai MC, Hsu LY, Chien KL, Yeh TL. Association between type 2 diabetes and osteoporosis risk: a representative cohort study in Taiwan. PLoS One. 2021;16(7):e0254451.
    1. LeBoff MS, Greenspan SL, Insogna KL, et al. The clinician's guide to prevention and treatment of osteoporosis. Osteoporos Int. 2022;33(10):2049‐2102.
    1. Pacheco‐Soto BT, Elguezabal‐Rodelo RG, Porchia LM, Torres‐Rasgado E, Pérez‐Fuentes R, Gonzalez‐Mejia ME. Denosumab improves glucose parameters in patients with impaired glucose tolerance: a systematic review and meta‐analysis. J Drug Assess. 2021;10(1):97‐105.
    1. Kiechl S, Wittmann J, Giaccari A, et al. Blockade of receptor activator of nuclear factor‐κB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus. Nat Med. 2013;19(3):358‐363.

MeSH terms

LinkOut - more resources